Rifagut (Rifaximin)

What It Is

Rifagut is a brand name (Opsonin Pharma) for rifaximin, a semi-synthetic derivative of rifamycin SV. It is a non-absorbable, broad-spectrum antibiotic that acts locally within the gastrointestinal tract. Systemic absorption after oral dosing is less than 0.5%, while fecal concentrations are extremely high (up to 8,000 mcg/g after a standard 3-day course). - Katzung's Basic and Clinical Pharmacology, 16th Ed.

Mechanism of Action

Rifaximin inhibits bacterial protein synthesis by binding to the beta subunit of DNA-dependent RNA polymerase, thereby blocking bacterial RNA transcription. It is bactericidal against both gram-positive and gram-negative aerobes and anaerobes. Because it stays in the gut lumen, it does not cause the systemic cytochrome P450-mediated drug interactions seen with other rifamycins (e.g., rifampicin). - Katzung's Basic and Clinical Pharmacology, 16th Ed.

Approved Indications & Doses

Indication	Dose	Duration
Traveler's Diarrhea (non-invasive E. coli, age ≥12 yrs)	200 mg TDS	3 days
Hepatic Encephalopathy (HE) - acute/secondary prophylaxis	400-550 mg BD	Long-term/indefinitely
IBS with Diarrhea (IBS-D)	550 mg TDS	14 days
Small Intestinal Bacterial Overgrowth (SIBO)	400 mg TDS	10 days
Diverticular disease (cyclic therapy)	400 mg BD	Cyclic (used with fiber)

Yamada's Textbook of Gastroenterology, 7th Ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics

Key Clinical Uses (Detailed)

1. Traveler's Diarrhea

Rifaximin (200 mg TDS for 3 days) is an established alternative to azithromycin and fluoroquinolones for uncomplicated traveler's diarrhea caused by non-invasive strains of E. coli. Important: It is NOT effective when diarrhea is complicated by fever and/or blood in stools (invasive organisms) - azithromycin is preferred in those cases. - Harrison's Principles of Internal Medicine 22E; Rosen's Emergency Medicine

2. Hepatic Encephalopathy (HE)

Rifaximin reduces ammonia production by suppressing ammonia-producing gram-negative bacilli in the gut. Used as:

Second-line monotherapy for acute HE (if lactulose intolerant): 400-550 mg BD
First-line adjunct to lactulose for secondary prophylaxis (preventing recurrence): 400-550 mg BD - continuation is indefinite after a first overt HE episode
Reduces readmissions and mortality in combination with lactulose
Yamada's Textbook of Gastroenterology; Sabiston Textbook of Surgery

3. IBS with Diarrhea (IBS-D)

Meta-analysis of multiple RCTs shows rifaximin 550 mg TDS is more efficacious than placebo for global IBS symptom improvement (OR favoring rifaximin). However, up to 64% of patients may relapse within 18 weeks, and repeat courses are effective. It modulates intestinal microbial function more than microbiota composition. - Yamada's Textbook of Gastroenterology; Harrison's Principles of Internal Medicine 22E

4. SIBO

Effective for small intestinal bacterial overgrowth regardless of whether associated with IBS. High fecal concentrations target the small bowel directly.

5. Recurrent C. difficile Infection

Used occasionally as an adjunct in refractory or recurrent CDI in adults (off-label). - Katzung's Basic and Clinical Pharmacology

Contraindications

Hypersensitivity to rifaximin, any rifamycin antibiotic, or any component of the formulation
Diarrhea with fever and/or bloody stools (invasive infection - rifaximin is ineffective)

Side Effects

Common side effects are generally mild given minimal systemic absorption:

Nausea, abdominal pain/flatulence
Headache
Peripheral edema (especially with HE patients who may have underlying cirrhosis/ascites)
Dizziness, fatigue
Raised liver function tests (uncommon)

Drug Interactions

Unlike other rifamycins, rifaximin has negligible CYP3A4-mediated drug interactions at standard doses due to its minimal absorption. In patients with normal liver function, it is not expected to induce CYP3A4.

Available Strengths

Rifagut 200 mg (traveler's diarrhea)
Rifagut 400 mg (HE, SIBO)
Rifagut 550 mg (HE prophylaxis, IBS-D)

Key Points to Remember

Non-absorbable - acts entirely within the GI lumen; systemic toxicity is minimal
Not for invasive diarrhea - ineffective when fever or blood in stool is present
Long-term use in HE - given indefinitely post-overt HE episode (with/without lactulose)
IBS-D relapse is common - retreatment for up to 3 courses is effective
No significant drug-drug interactions - unlike rifampicin

This is a shared conversation. Sign in to Orris to start your own chat.